share_log

In8bio | 8-K: IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

In8bio | 8-K: IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

In8bio | 8-K:In8bio公佈2024年第二季度財務業績和近期公司亮點
美股SEC公告 ·  2024/08/09 04:10

Moomoo AI 已提取核心訊息

IN8bio reported Q2 2024 financial results and received a Nasdaq deficiency notice for bid price below $1.00. The company posted a net loss of $8.6 million ($0.19 per share) compared to $7.7 million ($0.27 per share) in Q2 2023. Cash position stood at $10.2 million as of June 30, 2024, down from $21.3 million at 2023 year-end.The company presented positive Phase 1 data showing 100% one-year complete remission in evaluable leukemia patients for INB-100, with some patients remaining relapse-free for over three years. Additionally, 92% of glioblastoma patients treated with INB-200 exceeded median seven-month progression-free survival with standard care.Regarding the Nasdaq notice, IN8bio has until February 3, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period by transferring to Nasdaq Capital Market.
IN8bio reported Q2 2024 financial results and received a Nasdaq deficiency notice for bid price below $1.00. The company posted a net loss of $8.6 million ($0.19 per share) compared to $7.7 million ($0.27 per share) in Q2 2023. Cash position stood at $10.2 million as of June 30, 2024, down from $21.3 million at 2023 year-end.The company presented positive Phase 1 data showing 100% one-year complete remission in evaluable leukemia patients for INB-100, with some patients remaining relapse-free for over three years. Additionally, 92% of glioblastoma patients treated with INB-200 exceeded median seven-month progression-free survival with standard care.Regarding the Nasdaq notice, IN8bio has until February 3, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period by transferring to Nasdaq Capital Market.
In8bio報告了2024年第二季度的財務結果,並收到了納斯達克關於買盤價格低於$1.00的缺陷通知。公司公佈淨虧損爲860萬(每股$0.19),相比2023年第二季度的770萬(每股$0.27)有所增加。截止2024年6月30日,現金儲備爲1020萬,較2023年年末的2130萬下降。公司展示了積極的第一階段數據,顯示INb-100在可評估的白血病患者中實現100%的一年完全緩解,其中一些患者無復發超過三年。此外,接受標準治療的92%的膠質母細胞瘤患者在INb-200治療中超過了中位數七個月的無進展生存期。關於納斯達克的通知,In8bio有直到2025年2月3日的時間,通過在連續10個交易日內保持至少$1.00的收盤買盤價格來恢復合規。如果不成功,公司可能有資格通過轉移到納斯達克資本市場獲得額外180天的合規期。
In8bio報告了2024年第二季度的財務結果,並收到了納斯達克關於買盤價格低於$1.00的缺陷通知。公司公佈淨虧損爲860萬(每股$0.19),相比2023年第二季度的770萬(每股$0.27)有所增加。截止2024年6月30日,現金儲備爲1020萬,較2023年年末的2130萬下降。公司展示了積極的第一階段數據,顯示INb-100在可評估的白血病患者中實現100%的一年完全緩解,其中一些患者無復發超過三年。此外,接受標準治療的92%的膠質母細胞瘤患者在INb-200治療中超過了中位數七個月的無進展生存期。關於納斯達克的通知,In8bio有直到2025年2月3日的時間,通過在連續10個交易日內保持至少$1.00的收盤買盤價格來恢復合規。如果不成功,公司可能有資格通過轉移到納斯達克資本市場獲得額外180天的合規期。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息